Seven medicines recommended for approval by EMA
The EMA CHMP has given a positive opinion for marketing authorisation approval to seven medicines following its October meeting.
List view / Grid view
The EMA CHMP has given a positive opinion for marketing authorisation approval to seven medicines following its October meeting.
Marketing authorisation in the EU for Baqsimi, the first non-injectable treatment for very low levels of blood sugar, has been recommended by an EMA committee.
The global pharma contract development and manufacturing organisation (CDMO) outsourcing market is predicted to grow.
Increasing demand for convenient drug delivery, as well as an increase in diseases such as diabetes, has fuelled the global injectable drug delivery market.
GVOKE injection has received regulatory approval from the FDA for the treatment of severe hypoglycemia in patients with diabetes.
The seven centres will aid disease research and clinical development, improving access to patient data for studies.
The two pharmaceutical companies are facing a legal battle after Mylan filed a new drug application for a generic of Novo Nordisk’s Victoza.
The FDA has announced that it has granted approval to the first nine generic drug applications for Pfizer’s Lyrica treatment.
AstraZeneca has been issued with a complete response letter for Farxiga by the FDA meaning that it has rejected the treatment.
Seven medications have been suggested for removal from prescriptions by the NHS after a public consultation.
Researchers have discovered the formulation of glucagon fibrils, which could inform drug formulation for diabetic patients.
A new report predicts that the global diabetes drug market will rise to US$58.4 billion by 2025.
Pharmaceutical company, Sanofi, will eliminate jobs in France and Germany and end new in-house cardiology research programmes.
Global active pharmaceutical ingredients market set to surpass US$274.9 billion by 2026.
British Columbia has said it will switch as many as 20,400 patients from three branded biologic drugs to cheap biosimilars.